|
|
|
Price: $5.8500
$-0.04 
-0.679%
|
| Day's High:
| $6.0879
| Week Perf:
| -0.85 %
|
| Day's Low: |
$ 5.76 |
30 Day Perf: |
-21.48 % |
| Volume (M): |
165 |
52 Wk High: |
$ 16.63 |
| Volume (M$): |
$ 963 |
52 Wk Avg: |
$11.21 |
| Open: |
$5.84 |
52 Wk Low: |
$5.50 |
|
|
| Market Capitalization (Millions $) |
252 |
| Shares
Outstanding (Millions) |
43 |
| Employees |
43 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-165 |
| Cash Flow (TTM) (Millions $) |
30 |
| Capital Exp. (TTM) (Millions $) |
0 |
Abivax Sa
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Clinical Study
Published Thu, Oct 3 2024 6:31 AM UTC
Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by inflammation of the colon, resulting in a range of distressing symptoms. Current treatment options include aminosalicylates, corticosteroids, immunomodulators, and biologics; however, there remains a need for novel therapeutic agents that can effectively manage moderate to severe forms of the di...
|
| Per Share |
Current |
| Earnings (TTM) |
-3.84 $ |
| Revenues (TTM) |
-
|
| Cash Flow (TTM) |
0.7 $ |
| Cash |
6.55 $
|
| Book Value |
5.1 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-3.84 $
|
| Revenues (TTM) |
- |
| Cash Flow (TTM) |
0.7 $ |
| Cash |
6.55 $
|
| Book Value |
5.1 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
6.62%